← back to search

David S. Miller

Gynecologic Oncology Group ·
🔎 Find collaborators in Obstetrics and Gynecology · Reproductive Medicine →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Obstetrics and Gynecology · Reproductive Medicine
Research interest
Research interests include Endometrial and Cervical Cancer Treatments, Ovarian cancer diagnosis and treatment, Drug Transport and Resistance Mechanisms, and Cervical Cancer and HPV Research.
h-index
102
citations
43,397
works
1,002
NIH funding
primary concept
Medicine
email

Recent publications

Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026)
Journal of Clinical Oncology 2025cited by 5position: middledoi
NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024
Journal of the National Comprehensive Cancer Network 2024cited by 104position: middledoi
Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial
Journal of Clinical Oncology 2024cited by 23position: lastdoi
Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study
Gynecologic Oncology 2024cited by 20position: middledoi
Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma: NRG Oncology/GOG Study 279
Journal of Clinical Oncology 2024cited by 16position: middledoi
Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775
Journal of Clinical Oncology 2023cited by 139position: middledoi
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer
Journal of Clinical Oncology 2023cited by 70position: middledoi
GOG 3026 A phase II trial of letrozole + ribociclib in women with recurrent low-grade serous carcinoma of the ovary, fallopian tube or peritoneum: A GOG foundation study (001)
Gynecologic Oncology 2023cited by 22position: middledoi
Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician’s Choice
European Journal of Cancer 2023cited by 16position: middledoi
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022
Journal of the National Comprehensive Cancer Network 2022cited by 393position: middledoi
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network 2021cited by 707position: middledoi
Beyond Sedlis—A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis
Gynecologic Oncology 2021cited by 62position: middledoi
A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer
Gynecologic Oncology 2021cited by 39position: middledoi
Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)
Journal of Clinical Oncology 2020cited by 327position: firstdoi
Second-line lenvatinib in patients with recurrent endometrial cancer
Gynecologic Oncology 2020cited by 70position: middledoi
A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients.
Journal of Clinical Oncology 2020cited by 37position: middledoi
Safety and Efficacy Results of Retreatment With a PARP Inhibitor Monotherapy in Late-Line Recurrent Ovarian Cancer: Results From a Subset of the QUADRA Trial
Gynecologic Oncology 2020cited by 19position: middledoi
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
The Lancet Oncology 2019cited by 529position: middledoi
Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early-Stage Endometrial Cancer
Journal of Clinical Oncology 2019cited by 323position: lastdoi
Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study
Gynecologic Oncology 2019cited by 32position: middledoi
The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable
Alzheimer s & Dementia 2018cited by 141position: middledoi
Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study
Journal of Clinical Oncology 2018cited by 93position: lastdoi
Dementia clinical trial implications of mild behavioral impairment
International Psychogeriatrics 2018cited by 67position: middledoi
QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received ≥3 prior chemotherapy regimens.
Journal of Clinical Oncology 2018cited by 29position: middledoi
GOG 3007, a randomized phase II (RP2) trial of everolimus and letrozole (EL) or hormonal therapy (medroxyprogesterone acetate/tamoxifen, PT) in women with advanced, persistent or recurrent endometrial carcinoma (EC): A GOG Foundation study
Gynecologic Oncology 2018cited by 24position: lastdoi
The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations
Journal of Alzheimer s Disease 2017cited by 546position: middledoi
Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms
Alzheimer s & Dementia Translational Research & Clinical Interventions 2017cited by 387position: middledoi
New therapies for advanced, recurrent, and metastatic endometrial cancers
Gynecologic Oncology Research and Practice 2017cited by 108position: lastdoi
Mitochondrial mutations and metabolic adaptation in pancreatic cancer
Cancer & Metabolism 2017cited by 69position: middledoi
A Phase 3 Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High-Risk, Early-Stage Endometrial Cancer: A Gynecology Oncology Group Study
International Journal of Radiation Oncology*Biology*Physics 2017cited by 38position: lastdoi

Grants

Incubating the Use of Artificial Intelligence for Conducting High-Quality Research Syntheses
NSF2425651$499,9282024–2026PIRePORTER
Broadening the Discovery Potential of the LHC: Instrumentation, Algorithms, and Training for Physics with the ATLAS Experiment and Direct Axion Detection
NSF2310094$2,900,0002023–2027PIRePORTER
Collaborative Research: How to get SMAL: Studying island dwarfism to find Shared Molecular mechanisms Across Life history traits
NSF2222088$299,0442023–2027PIRePORTER
RAPID: Understanding and Supporting K-12 School Leaders' AI-related Decision-making
NSF2333764$189,9902023–2025PIRePORTER
Collaborative Research: SaTC: EDU: Dual-track Role-based Learning for Cybersecurity Analysts and Engineers for Effective Defense Operation with Data Analytics
NSF2228002$130,5572023–2027PIRePORTER
ECR Hub: Advancing the Long-Term Potential of Fundamental Research
NSF2208422$5,456,7632022–2027PIRePORTER
Identifying and Reducing Gender Bias in STEM: Systematically Synthesizing the Experimental Evidence
NSF2055422$1,067,4112021–2025PIRePORTER
Improving Undergraduates’ Motivation and Retention in STEM Through Classroom Interventions: A Meta-Analysis
NSF2110368$500,0002021–2026PIRePORTER
Building for Future Discoveries: Instrumentation, Algorithms, and Training for Physics with the ATLAS Experiment
NSF2013010$3,127,9772020–2024PIRePORTER
The Development of Gender Stereotypes About STEM Abilities: A Meta-Analysis
NSF1920401$499,8312019–2024PIRePORTER
Collaborative Research: Implementing Multi-institutional Classroom-based Undergraduate Research Experiences to Study the Impact of Environmental Changes on Salamander Populations
NSF1914791$64,0002019–2023PIRePORTER
CAREER: Boosting Signals for Hidden Supersymmetry with the ATLAS Hadronic Calorimeter
NSF1454815$985,5952015–2020PIRePORTER
BOOST 2015 Workshop Hosted by the Enrico Fermi Institute at the University of Chicago; Chicago, IL; August 10-14, 2015.
NSF1506139$7,0002015–2016PIRePORTER
Development of a Biology-Based Sperm Storage System
NSF1450227$299,9842014–2016PIRePORTER
Searches for New Physics with Heavy-Flavor Rich Hadronic Final States in the Post-Higgs Era
NSF1404465$155,0002014–2015PIRePORTER
Role of Excited Species in Plasma Enhanced Combustion
NSF0755632$412,1892008–2012PIRePORTER
Support for the Fourth Joint Meeting of the United States Sections of the Combustion Institute; Philadelphia, PA; March 20-23, 2005
NSF0456579$10,5002005–2006PIRePORTER
NEXT STEP: Recruiting and Supporting Associate Degree
NSF0422467$99,9012004–2009PIRePORTER
Acquisition of a Gas Chromatograph with Mass Selective Detector
NSF0214654$60,9802002–2003PIRePORTER
Collaborative Research: Implementation of Tabu Search for the Design of Novel Molecules using Parallel Computers
NSF0224887$50,0002002–2003PIRePORTER
Maximum Entropy Model Learning for Classification and More General Inference Tasks: Large-scale Applications and Extensions
NSF0082214$248,7812000–2005PIRePORTER
Collaborative Research: Vertical Divergence of Turbulent and Radiative Fluxes and Influence of Mesoscale Motions on Turbulence Intermittency
NSF9907092$90,1211999–2002PIRePORTER

Frequent collaborators

Gini F. Fleming · Sydney Local Health District7 papers (2012–2020)Paul DiSilvestro · AstraZeneca (Italy)7 papers (2012–2020)Robert S. Mannel · NRG Oncology6 papers (2012–2024)Bradley J. Monk · University of Cincinnati Medical Center5 papers (2018–2024)Virginia L. Filiaci · NRG Oncology5 papers (2012–2020)Krishnansu S. Tewari · Chapman University4 papers (2012–2021)Kathleen N. Moore · Oklahoma City University4 papers (2018–2020)Vicky Makker · University College London4 papers (2017–2023)Zahinoor Ismail · University of Calgary4 papers (2015–2018)Eric E. Smith · Rancho BioSciences (United States)4 papers (2015–2018)William Small · University of Michigan4 papers (2014–2024)Catheryn M. Yashar · University of San Diego3 papers (2014–2019)Sean M. Grimmond · University of Chicago3 papers (2012–2017) · 3 papers (2018–2020)Antonio Casado · Universidad Complutense de Madrid3 papers (2021–2023)Ursula A. Matulonis · Harvard University3 papers (2018–2020)Domenica Lorusso · Pontifícia Universidade Católica de São Paulo3 papers (2021–2023)Angeles Alvarez Secord · Duke University3 papers (2018–2020)Noelle Cloven · Texas Oncology3 papers (2018–2020)Amit M. Oza · University Health Network3 papers (2018–2020)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Obstetrics and Gynecology · Reproductive Medicine →